GMAB - Genmab hits 52-week low after Q3 Darzalex sales
2023-10-18 12:46:20 ET
More on Genmab
- Genmab Is Down To Attractive Levels
- Genmab A/S (GMAB) Q2 2023 Earnings Call Transcript
- Seagen, Genmab succeed in Phase 3 trial for cervical cancer therapy
- Genmab raises FY 2023 guidance on back of Darzalex sales
- Seeking Alpha’s Quant Rating on Genmab
For further details see:
Genmab hits 52-week low after Q3 Darzalex sales